Fulcrum Therapeutics, Inc.
Company Stats
- Market Cap
- $280.8M
- Nov 12, 2026 close
- Last Close
- $3.68
- Nov 12, 2026
- Shares Outstanding
- 76.3M
- Free Float
- 69.7%
Income Statement
- Revenue
- $0
- Operating Income
- -$84.8M
- Net Income
- -$74.9M
- EBITDA
- -$83.4M
Cash Flow
- Free Cash Flow
- -$60.4M
- FCF Yield
- -21.5%
- Owner FCF Yield
- -25.9%
Balance Sheet
- Cash & Equivalents
- $197.5M
Returns & Capital
- SBC, 3Y Avg
- $13.9M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $0 | -$60.4M | — |
| FY2024 | $80.0M | -$2.5M | -3.1% |
| FY2023 | $2.8M | -$91.5M | -3261.1% |
| FY2022 | $6.3M | -$99.0M | -1561.2% |
| FY2021 | $19.2M | -$80.2M | -418.5% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 3, 2026. Yields and enterprise value use the calculated market cap above, at the latest close. Ratios are our calculations from reported figures.